Cempra Inc Report issue

For profit Phase 2 Phase 3
Founded: Chapel Hill NC United States (2005)
Status: Acquired by Melinta Therapeutics (2017)

Organization Overview

First Clinical Trial
2009
NCT00948142
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis, Infectious (Phase 3)

Bacterial Infections (Phase 1)

Communicable Diseases (Phase 3)

Fatty Liver (Phase 2)

Gonorrhea (Phase 3)

Infections (Phase 3)

Lung Diseases (Phase 2)

Lung Diseases, Obstructive (Phase 2)

Non-alcoholic Fatty Liver Disease (Phase 2)

Pneumonia (Phase 3)

Pneumonia, Bacterial (Phase 3)

Pulmonary Disease, Chronic Obstructive (Phase 2)

Skin Diseases (Phase 2)

Skin Diseases, Bacterial (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 14
  • # of Trial APIs: 13